Pediatric Osteosarcoma: Identifying the elusive molecular signature and its relationship to this disease |
St. Jude Children's Research Hospital / Linda Hendershot, PhD |
Innovation Grants |
2019 |
Tennessee |
Novel Therapy of Heterogeneous B-cell Acute Lymphocytic Leukemia by Targeting Convergent Oncogenic Mediators STATs |
University of Alberta / Hasan Uludag, PhD |
Innovation Grants |
2019 |
Alberta |
Targeting microenvironment-induced TGFB signaling to overcome drug resistance in acute lymphoblastic leukemia |
St. Jude Children's Research Hospital / Charles Mullighan, MD |
Innovation Grants |
2019 |
Tennessee |
Targeting symmetric division in pediatric cancers |
Dana-Farber Cancer Institute / Rosalind Segal, MD/PhD |
Innovation Grants |
2019 |
Massachusetts |
Epigenetic regulation of genomic instability and its therapeutic implications in T-cell acute lymphoblastic leukemia |
Dana-Farber Cancer Institute / Birgit Knoechel, MD/PhD |
Innovation Grants |
2019 |
Massachusetts |
Norepinephrine Transporter-Targeted Pharmacotherapy of Aggressive Neuroblastoma |
Children's Hospital of Philadelphia / Michael Chorny, PhD |
Innovation Grants |
2019 |
Pennsylvania |
Selectively targeting EP300 with small molecules for neuroblastoma (NB) therapy |
Dana-Farber Cancer Institute / Jun Qi, PhD |
Innovation Grants |
2019 |
Massachusetts |
The use of hematopoietic stem and progenitor cells to reverse treatment resistance to PD-1 blockade |
University of Florida / Catherine Flores, PhD |
Innovation Grants |
2019 |
Florida |
Identify Novel Druggable Targets to Treat Philadelphia chromosome-like B-Acute Lymphoblastic Leukemia |
Children's Hospital of Philadelphia / Wei Tong, PhD |
Innovation Grants |
2019 |
Pennsylvania |
Using Splice Switching Oligonucleotides (SSOs) to target MDM2 for rhabdomyosarcoma therapy |
Research Institute at Nationwide Children's Hospital / Dawn Chandler, PhD |
Innovation Grants |
2019 |
Ohio |